A novel screening method to assess developability of antibody-like molecules

References

• Buss NAPS, Henderson SJ, McFarlane M, Shenton JM, De Haan L. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol 2012; 12:615-22
   PubMed Web of Science ®Google Scholar
• Maggon K. Monoclonal antibody “gold rush”. Curr Med Chem 2007; 14:1978-87; PMID:17691940; http://dx.doi.org/10.2174/092986707781368504
   PubMed Web of Science ®Google Scholar
• Ludwig DL, Pereira DS, Zhu Z, Hicklin DJ, Bohlen P. Monoclonal antibody therapeutics and apoptosis. Oncogene 2003; 22:9097-106; PMID:14663488; http://dx.doi.org/10.1038/sj.onc.1207104
   PubMed Web of Science ®Google Scholar
• Von Mehren M, Adams GP, Weiner LM. Monoclonal antibody therapy for cancer. Annu Rev Med 2003; 54:343-69; PMID:12525678; http://dx.doi.org/10.1146/annurev.med.54.101601.152442
   PubMed Web of Science ®Google Scholar
• Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science [Internet] 2013; 341:1192-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24031011; http://dx.doi.org/10.1126/science.1241145
   PubMed Web of Science ®Google Scholar
• Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD. Isolating and engineering human antibodies using yeast surface display. Nat Protoc 2006; 1:755-68; PMID:17406305; http://dx.doi.org/10.1038/nprot.2006.94
   PubMed Web of Science ®Google Scholar
• Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 1997; 15:553-7; PMID:9181578; http://dx.doi.org/10.1038/nbt0697-553
   PubMed Web of Science ®Google Scholar
• Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005; 23:1105-16; PMID:16151404; http://dx.doi.org/10.1038/nbt1126
   PubMed Web of Science ®Google Scholar
• Tiller T. Single B cell antibody technologies. N Biotechnol 2011; 28:453-7; PMID:21473940; http://dx.doi.org/10.1016/j.nbt.2011.03.014
   PubMed Web of Science ®Google Scholar
• Filpula D. Antibody engineering and modification technologies. Biomol Eng 2007; 24:201-15; PMID:17466589; http://dx.doi.org/10.1016/j.bioeng.2007.03.004
   PubMedGoogle Scholar
• Lee EC, Owen M. The application of transgenic mice for therapeutic antibody discovery. Methods Mol Biol 2012; 901:137-48; PMID:22723098; http://dx.doi.org/10.1007/978-1-61779-931-0_8
   PubMedGoogle Scholar
• Xu L, Kohli N, Rennard R, Jiao Y, Razlog M, Zhang K, Baum J, Johnson B, Tang J, Schoeberl B, et al. Rapid optimization and prototyping for therapeutic antibody-like molecules. MAbs 2013; 5:237-54; PMID:23392215; http://dx.doi.org/10.4161/mabs.23363
   PubMed Web of Science ®Google Scholar
• Dani B, Platz R, Tzannis ST. High concentration formulation feasibility of human immunoglubulin G for subcutaneous administration. J Pharm Sci 2007; 96:1504-17; PMID:17387698; http://dx.doi.org/10.1002/jps.20508
   PubMed Web of Science ®Google Scholar
• Yadav S, Liu J, Shire SJ, Kalonia DS. Specific interactions in high concentration antibody solutions resulting in high viscosity. J Pharm Sci 2010; 99:1152-68; PMID:19705420; http://dx.doi.org/10.1002/jps.21898
   PubMed Web of Science ®Google Scholar
• Connolly BD, Petry C, Yadav S, Demeule B, Ciaccio N, Moore JMR, Shire SJ, Gokarn YR. Weak interactions govern the viscosity of concentrated antibody solutions: high-throughput analysis using the diffusion interaction parameter. Biophys J 2012; 103:69-78; PMID:22828333; http://dx.doi.org/10.1016/j.bpj.2012.04.047
   PubMed Web of Science ®Google Scholar
• Ponsel D, Neugebauer J, Ladetzki-Baehs K, Tissot K. High affinity, developability and functional size: the holy grail of combinatorial antibody library generation. Molecules 2011; 16:3675-700; PMID:21540796; http://dx.doi.org/10.3390/molecules16053675
   PubMed Web of Science ®Google Scholar
• Saxena V, Panicucci R, Joshi Y, Garad S. Developability assessment in pharmaceutical industry: an integrated group approach for selecting developable candidates. J Pharm Sci 2009; 98:1962-79; PMID:18855914; http://dx.doi.org/10.1002/jps.21592
   PubMed Web of Science ®Google Scholar
• Yang X, Xu W, Dukleska S, Benchaar S, Mengisen S, Antochshuk V, Cheung J, Mann L, Babadjanova Z, Rowand J, et al. Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies. MAbs 2013; 5:787-94; PMID:23883920; http://dx.doi.org/10.4161/mabs.25269
   PubMed Web of Science ®Google Scholar
• Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Prediction of aggregation prone regions of therapeutic proteins. J Phys Chem B 2010; 114:6614-24; PMID:20411962; http://dx.doi.org/10.1021/jp911706q
   PubMed Web of Science ®Google Scholar
• Hawe A, Kasper JC, Friess W, Jiskoot W. Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress. Eur J Pharm Sci 2009; 38:79-87; PMID:19540340; http://dx.doi.org/10.1016/j.ejps.2009.06.001
   PubMed Web of Science ®Google Scholar
• Jacobs SA, Wu SJ, Feng Y, Bethea D, O'Neil KT. Cross-interaction chromatography: a rapid method to identify highly soluble monoclonal antibody candidates. Pharm Res 2010; 27:65-71; PMID:19911257; http://dx.doi.org/10.1007/s11095-009-0007-z
   PubMed Web of Science ®Google Scholar
• Liu Y, Caffry I, Wu J, Geng SB, Jain T, Sun T, Reid F, Cao Y, Estep P, Yu Y, et al. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy. MAbs 2014; 6:483-92; PMID:24492294; http://dx.doi.org/10.4161/mabs.27431
   PubMed Web of Science ®Google Scholar
• Sule SV, Dickinson CD, Lu J, Chow CK, Tessier PM. Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates. Mol Pharm 2013; 10:1322-31; PMID:23383873; http://dx.doi.org/10.1021/mp300524x
   PubMed Web of Science ®Google Scholar
• Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L, Christ D. Aggregation, stability, and formulation of human antibody therapeutics. Adv Protein Chem Struct Biol 2011; 84:41-61
   PubMed Web of Science ®Google Scholar
• Nieba L, Honegger A, Krebber C, Plückthun A. Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng 1997; 10:435-44; PMID:9194169; http://dx.doi.org/10.1093/protein/10.4.435
   PubMedGoogle Scholar
• Spencer S, Bethea D, Raju TS, Giles-Komar J, Feng Y. Solubility evaluation of murine hybridoma antibodies. MAbs 2012; 4:319-25; PMID:22531448; http://dx.doi.org/10.4161/mabs.19869
   PubMed Web of Science ®Google Scholar
• Lavinder JJ, Hari SB, Sullivan BJ, Magliery TJ. High-throughput thermal scanning: a general, rapid dye-binding thermal shift screen for protein engineering. J Am Chem Soc 2009; 131:3794-5; PMID:19292479; http://dx.doi.org/10.1021/ja8049063
   PubMed Web of Science ®Google Scholar
• Saito S, Hasegawa J, Kobayashi N, Kishi N, Uchiyama S, Fukui K. Behavior of monoclonal antibodies: relation between the second virial coefficient (B 2) at low concentrations and aggregation propensity and viscosity at high concentrations. Pharm Res 2012; 29:397-410; PMID:21853361; http://dx.doi.org/10.1007/s11095-011-0563-x
   PubMed Web of Science ®Google Scholar
• Tessier PM, Lenhoff AM, Sandler SI. Rapid measurement of protein osmotic second virial coefficients by self-interaction chromatography. Biophys J 2002; 82:1620-31; PMID:11867474; http://dx.doi.org/10.1016/S0006-3495(02)75513-6
   PubMed Web of Science ®Google Scholar
• Einaga Y, Abe F, Yamakawa H. Light-scattering method of determining the 2nd virial-coefficient for simple molecules and oligomers. J Phys Chem 1992; 96:3948-53; http://dx.doi.org/10.1021/j100189a008
   Web of Science ®Google Scholar
• Kheddo P, Tracka M, Armer J, Dearman RJ, Uddin S, Van Der Walle CF, Golovanov AP. The effect of arginine glutamate on the stability of monoclonal antibodies in solution. Int J Pharm 2014; 473:126-33; PMID:24992318; http://dx.doi.org/10.1016/j.ijpharm.2014.06.053
   PubMed Web of Science ®Google Scholar
• Goldberg DS, Bishop SM, Shah AU, Sathish HA. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability. J Pharm Sci [Internet] 2010; 100:1306-15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20960568; http://dx.doi.org/10.1002/jps.22371
   PubMed Web of Science ®Google Scholar